- Conditions
- Allan-Herndon-Dudley Syndrome
- Interventions
- Tiratricol
- Drug
- Lead sponsor
- Rare Thyroid Therapeutics International AB
- Industry
- Eligibility
- Up to 30 Months · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
- Interventions
- Tiratricol, Placebo
- Drug
- Lead sponsor
- Rare Thyroid Therapeutics International AB
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Kissimmee, Florida • Atlanta, Georgia • St Louis, Missouri + 3 more
- Conditions
- Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
- Interventions
- Tiratricol
- Drug
- Lead sponsor
- Rare Thyroid Therapeutics International AB
- Industry
- Eligibility
- Not listed
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Madera, California • San Diego, California + 13 more